356 related articles for article (PubMed ID: 34002026)
41. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
[TBL] [Abstract][Full Text] [Related]
42. Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis.
Moosazadeh M; Mousavi T
J Med Virol; 2022 Apr; 94(4):1350-1356. PubMed ID: 34850411
[TBL] [Abstract][Full Text] [Related]
43. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.
Klopfenstein T; Gendrin V; Kadiane-Oussou NJ; Conrozier T; Zayet S;
Rev Med Virol; 2022 Jan; 32(1):e2239. PubMed ID: 33882179
[TBL] [Abstract][Full Text] [Related]
44. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
[TBL] [Abstract][Full Text] [Related]
45. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
46. Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis.
Hernandez AV; Piscoya A; Pasupuleti V; Phan MT; Julakanti S; Khen P; Roman YM; Carranza-Tamayo CO; Escobedo AA; White CM
Am J Med; 2022 Nov; 135(11):1349-1361.e18. PubMed ID: 35878688
[TBL] [Abstract][Full Text] [Related]
47. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
48. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.
Malgie J; Schoones JW; Zeegers MP; Pijls BG
Sci Rep; 2021 Nov; 11(1):21522. PubMed ID: 34728658
[TBL] [Abstract][Full Text] [Related]
49. Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis.
De-Miguel-Balsa E; Estevan-Ortega R; Sempere-Selva MT; Latour-Pérez J; Baeza-Román A; Moya-Martinez A; Ramos-Rincon JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7151-7161. PubMed ID: 34859881
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
51. Tocilizumab in the Management of COVID-19: A Preliminary Report.
Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
[TBL] [Abstract][Full Text] [Related]
52. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
53. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.
Mutua V; Henry BM; Csefalvay CV; Cheruiyot I; Vikse J; Lippi G; Bundi B; Mong'are N
Acta Biomed; 2022 Mar; 93(1):e2022014. PubMed ID: 35315395
[TBL] [Abstract][Full Text] [Related]
54. Signals were broadly positive for months, but never definitive: the tocilizumab story.
Cozzi-Lepri A; Smith C; Mussini C
Clin Microbiol Infect; 2022 Mar; 28(3):371-374. PubMed ID: 34768021
[TBL] [Abstract][Full Text] [Related]
55. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
56. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
57. Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.
Malgie J; Schoones JW; Pijls BG
Clin Infect Dis; 2021 Jun; 72(11):e742-e749. PubMed ID: 32964913
[TBL] [Abstract][Full Text] [Related]
58. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
[TBL] [Abstract][Full Text] [Related]
59. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
Kow CS; Hasan SS
Eur J Clin Pharmacol; 2021 Aug; 77(8):1089-1094. PubMed ID: 33532896
[TBL] [Abstract][Full Text] [Related]
60. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
